TN2009000451A1 - Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor - Google Patents

Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Info

Publication number
TN2009000451A1
TN2009000451A1 TNP2009000451A TN2009000451A TN2009000451A1 TN 2009000451 A1 TN2009000451 A1 TN 2009000451A1 TN P2009000451 A TNP2009000451 A TN P2009000451A TN 2009000451 A TN2009000451 A TN 2009000451A TN 2009000451 A1 TN2009000451 A1 TN 2009000451A1
Authority
TN
Tunisia
Prior art keywords
reversible
intrvenous
inhibitor
acting
direct
Prior art date
Application number
TNP2009000451A
Other languages
English (en)
French (fr)
Inventor
Robert M Scarborough
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Phillips
Anjali Pandey
Huang Wolin
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of TN2009000451A1 publication Critical patent/TN2009000451A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2009000451A 2007-05-02 2009-10-30 Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor TN2009000451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
TN2009000451A1 true TN2009000451A1 (en) 2011-03-31

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000451A TN2009000451A1 (en) 2007-05-02 2009-10-30 Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101423483B1 (ko) * 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법
KR20090115953A (ko) * 2007-03-06 2009-11-10 노파르티스 아게 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
CA2686221A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2747310C (en) * 2008-12-30 2018-02-06 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2011060066A2 (en) 2009-11-11 2011-05-19 The Medicines Company Methods of treating or preventing stent thrombosis
ES2550033T3 (es) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
US20130165459A1 (en) 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US9029095B2 (en) 2010-12-01 2015-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method and kits for determining platelet susceptibility to activation in a patient
EP2646434B1 (en) * 2010-12-03 2019-05-15 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
KR102510832B1 (ko) 2017-03-15 2023-03-15 이도르시아 파마슈티컬스 리미티드 P2y12 수용체 안타고니스트의 피하 투여
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
KR101423483B1 (ko) 2005-11-03 2014-07-28 포톨라 파마슈티컬스, 인코포레이티드 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법

Also Published As

Publication number Publication date
US20120009172A1 (en) 2012-01-12
BRPI0811476A2 (pt) 2014-11-04
ECSP099778A (es) 2010-01-29
WO2008137753A3 (en) 2009-02-12
GT200900284A (es) 2012-01-31
JP2010526101A (ja) 2010-07-29
KR20100029746A (ko) 2010-03-17
MA31663B1 (fr) 2010-09-01
CN101795682A (zh) 2010-08-04
CA2686203A1 (en) 2008-11-13
EA200901473A1 (ru) 2010-06-30
WO2008137753A2 (en) 2008-11-13
US20090048216A1 (en) 2009-02-19
EP2079464A2 (en) 2009-07-22
MX2009011843A (es) 2010-04-22
AU2008247483A1 (en) 2008-11-13
CO6241104A2 (es) 2011-01-20
IL201834A0 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
TN2009000451A1 (en) Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
CY2023002I1 (el) Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης
IL211825A (en) Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
ECSP099376A (es) Inhibidores de la actividad de la akt
HN2009003002A (es) Compuestos de piridopirimidinonas inhibidores de pi3k-alfa
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
TR201907804T4 (tr) Apaf-1 inhibitör bileşikleri.
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
MY154898A (en) P70 s6 kinase inhibitors
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
PL2222294T3 (pl) Kompozycje zawierające pochodne polifenoli stylbenowych oraz ich zastosowanie do zwalczania patologii i starzenia się organizmów żywych
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2137175A4 (en) NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES
MX2010005714A (es) Compuestos de piridina.
SG158091A1 (en) Imidazoazepinone compounds